How to Get Retatrutide: Access Routes, Approval Timeline and Cost
Retatrutide has produced the largest weight reductions of any compound in trials, and it cannot be prescribed. That gap between demand and availability is the entire reason this page exists. There are three routes, and they are genuinely different in cost, risk and legality.
Route 1: clinical trial enrollment
The TRIUMPH program is running Phase 3 trials across multiple countries and indications: obesity (TRIUMPH-1), type 2 diabetes with obesity (TRIUMPH-2), severe obesity with established cardiovascular disease (TRIUMPH-3), and obesity with knee osteoarthritis (TRIUMPH-4), with obstructive sleep apnoea studied inside the first two rather than as its own trial. Participation costs nothing, includes medical supervision and monitoring, and gives access to pharmaceutical-grade material.
The trade-offs are real: you may be randomized to placebo, eligibility criteria are strict (BMI thresholds, comorbidity requirements, exclusion for prior GLP-1 use in some protocols), and sites are geographically limited. Listings are searchable on ClinicalTrials.gov by compound name and location — this is the only route that is both free and supervised.
Route 2: wait for approval
This timeline is now more concrete than it was. Alongside the TRIUMPH-2 and TRIUMPH-3 results in July 2026, Eli Lilly stated that it plans to submit a Biologics License Application to the FDA in the first quarter of 2027.
Three things that phrasing does not mean. It is a stated plan, not a filing that has happened. It is a submission date, not an approval date — FDA review of a standard application runs about ten months from acceptance, and a priority review about six, which puts the earliest realistic decision in late 2027 and more likely 2028. And approval is not guaranteed at the end of it. When and if it arrives, expect pricing in line with other branded incretin drugs — $1,000 or more per month at list price, less where insurance covers it.
Route 3: research-grade material
This is what most people mean when they ask how to get it. Research chemical suppliers sell retatrutide as a lyophilized powder under a research-use-only designation. It is legal to sell in that category, it is not an approved medicine, and no regulator has evaluated the manufacturing or purity of any particular vial.
Two consequences follow. First, quality varies enormously between suppliers — ourretatrutide supplier comparison reviews current vendors on price per milligram and published testing documentation, and that is the page for every sourcing question. Second, there is no medical supervision, no label, and no dosing guidance, in a compound whose tolerability depends heavily on correct titration.
What it actually costs
Vial price is the number suppliers advertise and the least useful one. Because retatrutide is titrated across a wide range, consumption at 12 mg weekly is six times consumption at 2 mg weekly — the dose determines cost far more than the vendor does. The dose levels below are the ones Phase 3 actually uses.
| Weekly dose | Monthly consumption | Approx. monthly cost |
|---|---|---|
| 2 mg (starting step) | ~8 mg | $35 – $70 |
| 4 mg (target, or a step) | ~16 mg | $70 – $140 |
| 6 mg (titration step only) | ~24 mg | $110 – $225 |
| 9 mg (target) | ~36 mg | $170 – $340 |
| 12 mg (highest target) | ~48 mg | $220 – $450 |
Larger vials and multi-vial orders usually improve cost per milligram more than switching suppliers does. Add the ancillaries — bacteriostatic water, insulin syringes, alcohol pads — which come to a small one-off cost but are not optional.
Price context
| Option | Monthly cost | Supervision | Quality assurance |
|---|---|---|---|
| Clinical trial | $0 | Full | Pharmaceutical grade |
| Research-grade retatrutide | $35 – $300 | None | Supplier COA only |
| Semaglutide (Wegovy, list) | ~$1,300 | Full | FDA approved |
| Tirzepatide (Zepbound, list) | ~$1,060 | Full | FDA approved |
That price gap is the reason the gray market exists, and it is worth naming plainly: what you save in money you pay in supervision and quality assurance. Whether that trade is acceptable is a personal decision, but it should be a conscious one rather than a hidden one.
Approved alternatives worth considering first
If the goal is weight loss rather than retatrutide specifically, tirzepatide is approved, produced about 21% reduction at 72 weeks in SURMOUNT-1, and has a prescription pathway plus manufacturer savings programs that bring real-world cost well below list. Semaglutide has the deepest evidence base and cardiovascular outcome data. Ourranked comparison covers how they differ.
Frequently asked questions
How do you get retatrutide?
There are two legitimate routes and one gray one. You can enrol in a Phase 3 clinical trial, which is free and medically supervised; you can wait for approval, which Eli Lilly has said it will apply for in the first quarter of 2027 — meaning a decision no earlier than late 2027; or you can buy research-grade material, which is legal to sell for laboratory use and is not an approved medicine.
How much does retatrutide cost per month?
At research-supplier prices, a 2 mg weekly protocol runs roughly $35–70 per month and a 9 mg protocol roughly $170–340, because dose drives consumption far more than vial price does. For comparison, approved GLP-1 medicines cost $500–1,300 per month without insurance.
Can a doctor prescribe retatrutide?
No. It has no FDA approval, so there is no legal prescription pathway in the United States. It also cannot be legally compounded as an approved-drug alternative, unlike the situation that existed for semaglutide during shortages.
When will retatrutide be approved?
Eli Lilly said in July 2026 that it plans to submit a Biologics License Application to the FDA in the first quarter of 2027. That is a submission date, not an approval date: FDA review runs roughly six to ten months from acceptance, which puts the earliest realistic decision in late 2027 and more plausibly 2028. It is also a plan, and plans move.
Is it legal to buy retatrutide?
Selling it labeled for research use is legal in the United States. Buying it is generally not prosecuted, but importing unapproved drugs can result in customs seizure, and marketing it for human use is not legal. Legality also varies significantly by country.
Sources
- Eli Lilly. TRIUMPH-1 topline results, 21 May 2026. Company announcement. Not peer-reviewed; presented at ADA, June 2026.
- Eli Lilly. TRIUMPH-1 sub-study results in obstructive sleep apnoea and knee osteoarthritis, 6 June 2026. Company announcement. Not peer-reviewed.
- Eli Lilly. TRIUMPH-2 and TRIUMPH-3 topline results and the stated Q1 2027 BLA submission plan, 23 July 2026. Company announcement. Not peer-reviewed.
- Phase 3 registry records: TRIUMPH-1 (NCT05929066), TRIUMPH-2 (NCT05929079), TRIUMPH-3 (NCT05882045), TRIUMPH-4 (NCT05931367).
- Giblin K et al. Retatrutide for the treatment of obesity, obstructive sleep apnoea and knee osteoarthritis: rationale and design of the TRIUMPH registrational clinical trials. Diabetes, Obesity and Metabolism, 2026;28(1):83–93. PubMed
- Eli Lilly TRIUMPH Phase 3 program, including TRIUMPH-1 (NCT05929066) and TRIUMPH-3 (NCT05882045). Search all sites: ClinicalTrials.gov.
- Jastreboff AM et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine, 2023;389(6):514–526. PubMed
- Manufacturer self-pay pricing, checked 2026: Wegovy (NovoCare) and Zepbound (Lilly). Prices change frequently — check the manufacturer page for the current figure.
- FDA. Human Drug Imports (personal importation policy criteria) and Personal Importation.
Related guides
- Retatrutide dosage and titration chart
- Retatrutide side effects
- Best place to buy retatrutide online: 2026 supplier comparison
- Best peptides for weight loss, ranked